title: A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.
abstract: BACKGROUND
  Consistent with other data sets, our own institutional series suggests that survival in patients aged ≥ 75 years with metastatic renal cell carcinoma (mRCC) is inferior to that in patients < 75 years. We sought to confirm these trends through exploration of the Surveillance, Epidemiology and End Results (SEER) registry.
  
  
  METHODS
  We assessed disease-specific survival (DSS) in 6204 patients with clear cell, papillary, or chromophobe mRCC diagnosed between 1992 and 2009, with the a priori hypothesis that DSS was shorter in patients aged ≥ 75 years. Analyses were further stratified by the period of diagnosis, either between 1992 and 2004 (the "cytokine era") or 2005 to 2009 (the "targeted therapy" era). Univariate and multivariate analyses were conducted to determine the association between clinicopathologic characteristics and DSS.
  
  
  RESULTS
  DSS was shorter in patients aged ≥ 75 years than in patients aged < 75 years (9 vs. 16 months; P < .0001). In patients 18 to 74 years, DSS was superior in the targeted therapy era compared with the cytokine era (P < .0001). However, in patients ≥ 75 years, no difference in DSS was noted between these periods (P = .90). On multivariate analysis, age ≥ 75 years, female sex, diagnosis during the cytokine era, node-positive disease, and absence of cytoreductive nephrectomy were independently associated with DSS.
  
  
  CONCLUSIONS
  DSS appears to be inferior in older adults with mRCC (specifically, patients aged ≥ 75 years). Furthermore, in contrast to their younger counterparts, no improvement in DSS was seen in older adults in the transition from the cytokine era to the targeted therapy era.
authors: Division of Biostatistics, Department of Information Science, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
authors: Rebecca A
authors: RA
authors: Nelson
authors: Nicholas
authors: N
authors: Vogelzang
authors: Sumanta K
authors: SK
authors: Pal
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009369:Neoplasms; D009392:Nephrectomy; D012042:Registries; D018426:SEER Program; D013534:Survival; D016896:Treatment Outcome
keywords: Cytokine; Metastatic renal cell carcinoma; Older adults; Survival; Targeted therapy; Trends
references: Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6302S-3S
references: 15448021
references: Oncology (Williston Park). 2009 Mar;23(3):288-95
references: 19418830
references: Clin Genitourin Cancer. 2012 Jun;10(2):93-8
references: 22382008
references: J Clin Oncol. 1995 Mar;13(3):688-96
references: 7884429
references: J Clin Oncol. 2009 Dec 1;27(34):5794-9
references: 19826129
references: Lancet Oncol. 2012 Aug;13(8):827-37
references: 22759480
references: Jpn J Clin Oncol. 2011 Jan;41(1):110-4
references: 20802005
references: J Clin Oncol. 2011 Apr 1;29(10):1290-6
references: 21357782
references: Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9090-5
references: 12840146
references: Semin Oncol. 2006 Oct;33(5):583-7
references: 17045087
references: JAMA. 2004 May 26;291(20):2441-7
references: 15161894
references: J Clin Oncol. 2002 Jan 1;20(1):289-96
references: 11773181
references: Eur Urol. 2012 Apr;61(4):826-33
references: 22297244
references: Mol Cancer Ther. 2010 Dec;9(12):3115-25
references: 21078774
references: J Geriatr Oncol. 2013 Apr;4(2):128-33
references: 23646100
references: Oncology. 2010;78(5-6):340-7
references: 20733337
references: Urol Oncol. 2014 Jan;32(1):23.e9-13
references: 23453468